These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 15062175)

  • 21. A dose-response analysis of biochemical control outcomes after (125)I monotherapy for patients with favorable-risk prostate cancer.
    Shiraishi Y; Yorozu A; Ohashi T; Toya K; Saito S; Nishiyama T; Yagi Y; Shigematsu N
    Int J Radiat Oncol Biol Phys; 2014 Dec; 90(5):1069-75. PubMed ID: 25539368
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Candidates for prostate radioactive seed implantation treated by external beam radiotherapy.
    Seung SK; Kroll S; Wilder RB; Posner MD; Roach M
    Cancer J Sci Am; 1998; 4(3):168-74. PubMed ID: 9612598
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancer.
    Zelefsky MJ; Wallner KE; Ling CC; Raben A; Hollister T; Wolfe T; Grann A; Gaudin P; Fuks Z; Leibel SA
    J Clin Oncol; 1999 Feb; 17(2):517-22. PubMed ID: 10080594
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
    Kupelian P; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A; Kuban D
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):795-9. PubMed ID: 15925452
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prostate-specific antigen bounce after prostate seed implantation for localized prostate cancer: descriptions and implications.
    Stock RG; Stone NN; Cesaretti JA
    Int J Radiat Oncol Biol Phys; 2003 Jun; 56(2):448-53. PubMed ID: 12738319
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Segmental dosimetry, toxicity and long-term outcome in patients with prostate cancer treated with permanent seed implants.
    Meyer A; Wassermann J; Warszawski-Baumann A; Baumann R; Machtens S; Karstens JH; Christiansen H; Merseburger A; Kuczyk MA; von Klot C
    BJU Int; 2013 May; 111(6):897-904. PubMed ID: 23305079
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of cigarette smoking on biochemical outcome after permanent prostate brachytherapy.
    Merrick GS; Butler WM; Wallner KE; Galbreath RW; Lief JH; Adamovich E
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1056-62. PubMed ID: 15001245
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prophylactic versus therapeutic alpha-blockers after permanent prostate brachytherapy.
    Merrick GS; Butler WM; Wallner KE; Lief JH; Galbreath RW
    Urology; 2002 Oct; 60(4):650-5. PubMed ID: 12385927
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reductions in prostatic doses are associated with less acute morbidity in patients undergoing Pd-103 brachytherapy: Substantiation of the rationale for focal therapy.
    Ferro A; Bae HJ; Yenokyan G; Le Y; McNutt T; Mian O; Gergis C; Haviland C; DeWeese TL; Song DY
    Brachytherapy; 2018; 17(2):313-318. PubMed ID: 29174937
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995.
    Kupelian P; Kuban D; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A
    Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):415-9. PubMed ID: 15667961
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Review on the effectiveness of prostate cancer brachytherapy].
    Inciūra A; Jarusevicus L; Vaiciūnas K; Juozaityte E
    Medicina (Kaunas); 2009; 45(8):660-71. PubMed ID: 19773626
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interim report of image-guided conformal high-dose-rate brachytherapy for patients with unfavorable prostate cancer: the William Beaumont phase II dose-escalating trial.
    Martinez AA; Kestin LL; Stromberg JS; Gonzalez JA; Wallace M; Gustafson GS; Edmundson GK; Spencer W; Vicini FA
    Int J Radiat Oncol Biol Phys; 2000 May; 47(2):343-52. PubMed ID: 10802358
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Postimplant dosimetry for (125)I prostate implants: definitions and factors affecting outcome.
    Stock RG; Stone NN; Lo YC; Malhado N; Kao J; DeWyngaert JK
    Int J Radiat Oncol Biol Phys; 2000 Oct; 48(3):899-906. PubMed ID: 11020588
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Factors predicting for urinary incontinence after prostate brachytherapy.
    McElveen TL; Waterman FM; Kim H; Dicker AP
    Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1395-404. PubMed ID: 15275725
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 125I versus 103Pd for low-risk prostate cancer: preliminary PSA outcomes from a prospective randomized multicenter trial.
    Wallner K; Merrick G; True L; Sutlief S; Cavanagh W; Butler W
    Int J Radiat Oncol Biol Phys; 2003 Dec; 57(5):1297-303. PubMed ID: 14630265
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Morbidity effect of the time gap between supplemental beam radiation and Pd-103 prostate brachytherapy.
    Corriveau J; Wallner K; Merrick G; True L; Cavanagh W; Sutlief S; Butler W
    Brachytherapy; 2003; 2(2):108-13. PubMed ID: 15062149
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prostate specific antigen findings and biopsy results following interactive ultrasound guided transperineal brachytherapy for early stage prostate carcinoma.
    Stock RG; Stone NN; DeWyngaert JK; Lavagnini P; Unger PD
    Cancer; 1996 Jun; 77(11):2386-92. PubMed ID: 8635111
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The correlation between D90 and outcome for I-125 seed implant monotherapy for localised prostate cancer.
    Ash D; Al-Qaisieh B; Bottomley D; Carey B; Joseph J
    Radiother Oncol; 2006 May; 79(2):185-9. PubMed ID: 16701911
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictive factors for acute and late urinary toxicity after permanent prostate brachytherapy: long-term outcome in 712 consecutive patients.
    Keyes M; Miller S; Moravan V; Pickles T; McKenzie M; Pai H; Liu M; Kwan W; Agranovich A; Spadinger I; Lapointe V; Halperin R; Morris WJ
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1023-32. PubMed ID: 19111402
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.